Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (Nasdaq: NRIX) closed an underwritten registered offering of 24,485,799 shares of common stock at $10.21 per share, generating $250.0 million gross proceeds on October 27, 2025.

Nurix said it intends to use net proceeds primarily to fund clinical development of bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL), explore autoimmune indications, support R&D to expand the pipeline, and for working capital and general corporate purposes. The offering included new and existing institutional investors and was led by J.P. Morgan, Jefferies, and Stifel.

Nurix Therapeutics (Nasdaq: NRIX) priced an underwritten registered offering of 24,485,799 shares of common stock at $10.21 per share, for expected gross proceeds of $250.0 million.

The offering is expected to close on or about October 23, 2025, subject to customary closing conditions, and includes participation from new and existing investors such as General Atlantic and Redmile Group. Joint book‑running managers are J.P. Morgan, Jefferies, and Stifel.

Nurix intends to use net proceeds primarily to fund clinical development of bexobrutideg (NX‑5948) in CLL, explore autoimmune indications, expand R&D pipeline, and for working capital and general corporate purposes.

Nurix (Nasdaq: NRIX) initiated the DAYBreak pivotal single-arm Phase 2 study of bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia (r/r CLL) on October 22, 2025. The program will evaluate a 600 mg once-daily oral dose cleared by global regulators for pivotal monotherapy trials and seeks data to support a potential Accelerated Approval.

Nurix plans a randomized confirmatory Phase 3 to start in the first half of 2026 comparing bexobrutideg to pirtobrutinib, bendamustine + rituximab, or idelalisib + rituximab. An investor webcast occurred October 22, 2025 at 8:00 a.m. EDT reviewing preclinical data and program updates.

Nurix Therapeutics (NASDAQ: NRIX) reported Phase 1a data for NX-1607, a first-in-class oral CBL-B inhibitor, presented at ESMO 2025.

In 82 treated patients (71 evaluable as of July 26, 2025) across 5–80 mg total daily doses, NX-1607 showed dose-dependent exposure, peripheral immune activation, reductions in tumor biomarkers (PSA, CEA), tumor shrinkage, long-term stable disease, and a confirmed partial response in a patient with MSS colorectal cancer. The disease control rate was 49.3%. Six patients had immune-related adverse events; most treatment-emergent adverse events were Grade ≤2. Data support initiating expansion cohorts at the two highest doses as monotherapy or in combination for advanced solid tumors.

Nurix Therapeutics (Nasdaq: NRIX) reported Q3 2025 results and program updates on Oct 9, 2025. The company plans to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL in H2/Q4 2025, including a single‑arm path for potential accelerated approval and a randomized Phase 3 confirmatory trial. Encore Phase 1 data showed ORR 80.9% in CLL and ORR 84.2% in WM. Preclinical data for IRAK4 degrader GS-6791 were presented. Cash and marketable securities were $428.8M as of Aug 31, 2025.

Nurix Therapeutics (Nasdaq: NRIX) presented preclinical data for GS-6791, a novel IRAK4 protein degrader, at the EADV Congress in Paris. The data demonstrates the drug's effectiveness in treating inflammatory diseases through potent IRAK4 degradation and inhibition of IL-1 and IL-36 signaling pathways.

Key findings show that GS-6791 achieved near-complete IRAK4 knockdown in human blood and keratinocytes, reduced proinflammatory cytokines, and improved barrier function in dermatitis models. The compound, developed in collaboration with Gilead Sciences, is currently in a Phase 1 clinical trial evaluating its safety and tolerability in healthy volunteers.

Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in multiple investor conferences during September 2025.

The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, CCO John Northcott, and CBO Jason Kantor, will attend five major healthcare conferences: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley, and Stifel Virtual Immunology Forum. All presentations will be webcast live and available for 30 days through Nurix's website.

Nurix Therapeutics (Nasdaq: NRIX) reported significant progress in Q2 2025, highlighted by positive clinical developments and strategic collaborations. The company presented updated data for bexobrutideg (NX-5948), showing an impressive 80.9% objective response rate in r/r CLL patients. Nurix secured a $15M license fee from Sanofi's STAT6 collaboration extension and received FDA clearance for IRAK4 degrader GS-6791/NX-0479.

Financial highlights include Q2 2025 revenue of $44.1M, up from $12.1M year-over-year, and a strong cash position of $485.8M. R&D expenses increased to $78.1M from $48.9M, while net loss improved to $43.5M ($0.52 per share) compared to $44.5M ($0.71 per share) in Q2 2024.

Nurix Therapeutics (Nasdaq: NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation from the European Medicines Agency for treating lymphoplasmacytic lymphoma, also known as Waldenström macroglobulinemia (WM).

The designation provides significant benefits including 10 years of market exclusivity in the EU upon approval, protocol assistance, and reduced regulatory fees. Bexobrutideg, an oral BTK degrader, is currently in Phase 1a/b clinical trials for relapsed or refractory B-cell malignancies.

The drug has already received multiple regulatory designations, including FDA Fast Track for WM and CLL/SLL treatment, and EMA PRIME designation for CLL/SLL treatment, demonstrating strong regulatory momentum.